Related Experiment Video
Updated: Feb 9, 2026

Mycorrhizal Maps as a Tool to Explore Colonization Patterns and Fungal Strategies in the Roots of Festuca rubra and Zea mays
Published on: August 26, 2022
Secukinumab emerges as a rapidly effective therapy for pityriasis rubra pilaris
Lauren Bonomo1, Jacob O Levitt1
1Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Abstract:
Refractory pityriasis rubra pilaris (PRP) often is treated off-label with the same biologic therapies that are approved for the treatment of psoriasis, most commonly tumor necrosis factor (TNF) α antagonists and ustekinumab; however, the IL-17A antagonist secukinumab also has shown efficacy in the treatment of PRP. We report 2 new cases of severe refractory PRP that responded rapidly to treatment with secukinumab.
More Related Videos
Related Concept Videos
Emerging Adulthood
Gene Therapy
Introduction Cardiac Emergencies
Applications of GIS: Disaster Management and Emergency Response
Group Therapy
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...

